Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 20, 2015, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.57 to $48,050,000.00.

Highlighted Stocks Traded by Insiders:

Cumberland Pharmaceuticals (CPIX) - FREE Research Report

Lawrence Thomas R, who is Director at Cumberland Pharmaceuticals, sold 6,000 shares at $6.95 on March 20, 2015. Following this transaction, the Director owned 49,381 shares meaning that the stake was reduced by 10.83% with the 6,000-share transaction.

The shares most recently traded at $6.91, down $0.04, or 0.58% since the insider transaction. Historical insider transactions for Cumberland Pharmaceuticals go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 10,000

The average volume for Cumberland Pharmaceuticals has been 26,000 shares per day over the past 30 days. Cumberland Pharmaceuticals has a market cap of $117.5 million and is part of the health care sector and drugs industry. Shares are up 15.89% year-to-date as of the close of trading on Friday.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company has a P/E ratio of 49.5. Currently, there are no analysts who rate Cumberland Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPIX - FREE

TheStreet Quant Ratings

rates Cumberland Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full

TheStreet Recommends

Cumberland Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Guidewire Software (GWRE) - FREE Research Report

Weatherford Clifton Thomas, who is Director at Guidewire Software, sold 5,000 shares at $53.42 on March 20, 2015. Following this transaction, the Director owned 28,079 shares meaning that the stake was reduced by 15.12% with the 5,000-share transaction.

Hung Priscilla, who is Chief Administrative Officer at Guidewire Software, sold 4,001 shares at $52.60 on March 20, 2015. Following this transaction, the Chief Administrative Officer owned 0 shares meaning that the stake was reduced by 100% with the 4,001-share transaction.

King James Winston, who is General Counsel and Secretary at Guidewire Software, sold 1,203 shares at $52.55 on March 20, 2015. Following this transaction, the General Counsel and Secretary owned 0 shares meaning that the stake was reduced by 100% with the 1,203-share transaction.

The shares most recently traded at $52.55, up $0.00, or 0.01% since the insider transaction. Historical insider transactions for Guidewire Software go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 188,621

The average volume for Guidewire Software has been 332,800 shares per day over the past 30 days. Guidewire Software has a market cap of $3.7 billion and is part of the technology sector and computer software & services industry. Shares are up 5.96% year-to-date as of the close of trading on Friday.

Guidewire Software, Inc. provides software products for property and casualty (P&C) insurers. It offers an integrated suite of software applications that address the core processes, such as underwriting and policy administration, claims management, and billing. The company has a P/E ratio of 188.6. Currently, there are 3 analysts who rate Guidewire Software a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GWRE - FREE

TheStreet Quant Ratings

rates Guidewire Software as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Guidewire Software Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Advent Software (ADVS) - FREE Research Report

Hess David Peter, who is Chief Executive Officer at Advent Software, sold 3,769 shares at $44.21 on March 20, 2015. Following this transaction, the Chief Executive Officer owned 159,459 shares meaning that the stake was reduced by 2.31% with the 3,769-share transaction.

The shares most recently traded at $44.24, up $0.03, or 0.07% since the insider transaction. Historical insider transactions for Advent Software go as follows:

  • 4-Week # shares sold: 1,731
  • 12-Week # shares sold: 14,297
  • 24-Week # shares sold: 39,647

The average volume for Advent Software has been 1.2 million shares per day over the past 30 days. Advent Software has a market cap of $2.3 billion and is part of the technology sector and computer software & services industry. Shares are up 44.35% year-to-date as of the close of trading on Friday.

Advent Software, Inc. provides software products and services worldwide. The company offers its products and services for automating and integrating data and work flows across the investment management organization, as well as between the investment management organization and external parties. The stock currently has a dividend yield of 1.18%. The company has a P/E ratio of 47.0. Currently, there is 1 analyst who rates Advent Software a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADVS - FREE

TheStreet Quant Ratings

rates Advent Software as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full

Advent Software Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null